Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8408655 | 0.85 | NQO1 (0.30) | NQO1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5754501 | 0.85 | HTR2C (0.35) | HTTTUBB1 | |
| SCHEMBL13723603 | 0.84 | NCF1 (0.34) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL159471 | 0.83 | TSHR (0.36) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL13722888 | 0.82 | NR5A1 (0.36) | HTT | |
| SCHEMBL28130967 | 0.81 | PTPN1 (0.31) | — | |
| SCHEMBL13723015 | 0.80 | NR5A1 (0.39) | — | |
| SCHEMBL13722453 | 0.79 | SQOR (0.32) | — | |
| SCHEMBL13723687 | 0.79 | ALDH1A1 (0.35) | — | |
| SCHEMBL13723489 | 0.78 | HTR2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-113549018-B | Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-02-27 | — | — | CN | claimed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | claimed |
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | claimed |
| CN-113549018-A | Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-10-26 | — | — | CN | claimed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | claimed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | claimed |
| CN-112010844-A | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2020-12-01 | — | — | CN | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | claimed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | claimed |
| JP-2625190-B2 | — | — | 1997-07-02 | — | — | JP | claimed |
| EP-0296316-B1 | 1,4-DIHYDROPYRIDINE ENANTIOMERS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1993-09-01 | — | — | EP | claimed |
| US-4994461-A | Vasodilators; treating cardiovascular disorders | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-02-19 | — | — | US | claimed |
| EP-0343193-A1 | 1,4-DIHYDROPYRIDINE ENANTIOMERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1989-11-29 | — | — | EP | claimed |
| EP-0296316-A1 | 1,4-Dihydropyridine enantiomers | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1988-12-28 | — | — | EP | claimed |
| WO-1988007531-A1 | NEW OPTICALLY ACTIVE COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-10-06 | — | — | WO | claimed |
| WO-1988007525-A1 | 1,4-DIHYDROPYRIDINE ENANTIOMERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-10-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | NQO1 785/4885L3MBTL1 4109/4885CYP1A2 116/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | NQO1 1027/4885L3MBTL1 4017/4885CYP1A2 103/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NQO1 3/4885L3MBTL1 2990/4885CYP1A2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.